Worst-Itch Numeric Rating Scale 2 As with the Skin Pain-NRS, the WI-NRS uses a 24-hour period to evaluate the worst itch and on a 0 (no itch) to 10 (worst imaginable itch) scale.

Lebrikizumab provided sustained itch relief and improved sleep quality through 52 weeks in individuals with ...

A new trial finds guselkumab is highly effective and well tolerated for moderate to severe scalp psoriasis in individuals ...

The primary endpoint was the proportion of patients with improvement (reduction) in worst-itch numeric rating scale (WI-NRS) score of 4 or greater at week 12 from baseline.

Within an hour, the patient reported that her itchiness had improved significantly, to 1 out of 10 on the Worst Itch Numeric Rating Scale. This positive response continued for 5 weeks without any ...

Apogee's APG777 showed a 71% drop in eczema severity and strong itch relief in a Phase 2 trial for atopic dermatitis. Part B ...

"Within 10 minutes after the initial administration, her Worst Itch Numeric Rating Scale (WI-NRS) score improved from 10 of 10 to 4 of 10," her doctors wrote in the JAMA report.

To learn more about the data, view the full text of “Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch ...

VANCOUVER, British Columbia — Patients with moderate-to-severe psoriasis treated with ixekizumab reported greater and more rapid improvement in itch severity compared with patients treated with ...

The primary outcome was change in the weekly average of the daily 0 to 10 Worst Itch Numeric Rating Scale, for which 0 is "no itch" and 10 is "worst itch imaginable." ...

The primary endpoint was the proportion of patients with improvement (reduction) in the worst-itch numeric rating scale (WI-NRS) by at least 4-points at week 24 from baseline.

In patients with atopic dermatitis, ruxolitinib cream significantly reduced itch during two phase 3 trials. The randomized, double blind, vehicle controlled, identical design TRuE AD 1 and TRuE AD ...